As Clorox Co Del (CLX) Market Valuation Declined, Shareholder First Republic Investment Management Trimmed Its Stake; Pentwater Capital Management LP Upped Esperion Therapeutics (ESPR) Position by $12.76 Million as Shares Rose

February 19, 2018 - By wolcottdaily

Matthew Halbower increased its stake in Esperion Therapeutics Inc (ESPR) by 12.84% based on its latest 2017Q3 regulatory filing with the SEC. Pentwater Capital Management Lp bought 255,200 shares as the company’s stock rose 33.24% with the market. The hedge fund run by Matthew Halbower held 2.24M shares of the health care company at the end of 2017Q3, valued at $112.43M, up from 1.99M at the end of the previous reported quarter. Pentwater Capital Management Lp who had been investing in Esperion Therapeutics Inc for a number of months, seems to be bullish on the $1.96 billion market cap company. The stock increased 0.46% or $0.34 during the last trading session, reaching $74.92. About 371,409 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since February 19, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

First Republic Investment Management Inc decreased its stake in Clorox Co Del (CLX) by 12.26% based on its latest 2017Q3 regulatory filing with the SEC. First Republic Investment Management Inc sold 23,105 shares as the company’s stock declined 1.16% while stock markets rallied. The hedge fund held 165,388 shares of the specialty chemicals company at the end of 2017Q3, valued at $21.82 million, down from 188,493 at the end of the previous reported quarter. First Republic Investment Management Inc who had been investing in Clorox Co Del for a number of months, seems to be less bullish one the $17.04B market cap company. The stock increased 0.51% or $0.67 during the last trading session, reaching $131.7. About 1.09M shares traded or 8.65% up from the average. The Clorox Company (NYSE:CLX) has risen 1.68% since February 19, 2017 and is uptrending. It has underperformed by 15.02% the S&P500.

Investors sentiment increased to 1.1 in Q3 2017. Its up 0.15, from 0.95 in 2017Q2. It is positive, as 43 investors sold CLX shares while 223 reduced holdings. 57 funds opened positions while 236 raised stakes. 90.68 million shares or 2.85% more from 88.17 million shares in 2017Q2 were reported. Delta Asset Ltd Limited Liability Company Tn reported 131 shares stake. Kentucky-based Community Tru Investment Commerce has invested 0.14% in The Clorox Company (NYSE:CLX). Guardian Life Insurance Of America has 288 shares. Cullen Frost Bankers Inc reported 49,836 shares or 0.22% of all its holdings. West Oak Cap Ltd Liability Co reported 1,400 shares or 0.11% of all its holdings. Winch Advisory Svcs Ltd Liability Company reported 0% in The Clorox Company (NYSE:CLX). Assetmark stated it has 151 shares. Commonwealth Of Pennsylvania Pub School Empls Retrmt System has 0.02% invested in The Clorox Company (NYSE:CLX) for 10,497 shares. Fmr Ltd holds 0% or 101,708 shares in its portfolio. Howland Cap Management Ltd Co has invested 0.02% in The Clorox Company (NYSE:CLX). Aqr Lc reported 0.04% stake. Ycg invested 0.1% in The Clorox Company (NYSE:CLX). Cap Counsel stated it has 0.13% in The Clorox Company (NYSE:CLX). Employees Retirement Systems Of Ohio reported 54,467 shares. Teacher Retirement Sys Of Texas holds 30,943 shares.

First Republic Investment Management Inc, which manages about $25.99 billion and $13.89B US Long portfolio, upped its stake in Equifax Inc (NYSE:EFX) by 136,156 shares to 147,407 shares, valued at $15.62 million in 2017Q3, according to the filing. It also increased its holding in Disney Walt Co (NYSE:DIS) by 16,893 shares in the quarter, for a total of 886,469 shares, and has risen its stake in Mcdonalds Corp (NYSE:MCD).

Since August 23, 2017, it had 0 insider purchases, and 1 insider sale for $297,804 activity. Foster James E sold 9,861 shares worth $1.37M. Balousek Jon M sold $1.28 million worth of stock or 9,223 shares.

Among 16 analysts covering The Clorox Company (NYSE:CLX), 3 have Buy rating, 1 Sell and 12 Hold. Therefore 19% are positive. The Clorox Company had 51 analyst reports since August 5, 2015 according to SRatingsIntel. On Friday, May 5 the stock rating was maintained by BMO Capital Markets with “Buy”. The stock of The Clorox Company (NYSE:CLX) has “Equal Weight” rating given on Monday, January 9 by Barclays Capital. UBS maintained it with “Sell” rating and $105 target in Tuesday, November 3 report. RBC Capital Markets maintained The Clorox Company (NYSE:CLX) on Friday, June 30 with “Hold” rating. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, December 16. The stock has “Underweight” rating by Barclays Capital on Wednesday, October 7. Consumer Edge Research upgraded the stock to “Outperform” rating in Friday, November 10 report. The firm earned “Equal-Weight” rating on Monday, February 5 by Morgan Stanley. The rating was maintained by JP Morgan with “Underweight” on Wednesday, May 4. The stock of The Clorox Company (NYSE:CLX) has “Sell” rating given on Thursday, August 4 by UBS.

Pentwater Capital Management Lp, which manages about $5.28 billion and $11.65 billion US Long portfolio, decreased its stake in Digitalglobe Inc (NYSE:DGI) by 87,100 shares to 712,900 shares, valued at $25.13 million in 2017Q3, according to the filing. It also reduced its holding in Vmware Inc (Put) by 4,500 shares in the quarter, leaving it with 45,500 shares, and cut its stake in Nxp Semiconductors N V (NASDAQ:NXPI).

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Esperion Therapeutics had 53 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Chardan Capital Markets on Friday, February 26. The stock has “Buy” rating by Cowen & Co on Wednesday, October 18. Chardan Capital Markets maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Monday, August 31 with “Sell” rating. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Neutral” rating by JP Morgan on Wednesday, June 29. The stock has “Buy” rating by Citigroup on Tuesday, February 28. The firm earned “Buy” rating on Monday, October 26 by Lake Street. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Buy” rating by Bank of America on Friday, January 5. The company was maintained on Wednesday, October 18 by Needham. The firm has “Buy” rating by Jefferies given on Wednesday, August 9. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, January 15 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: